12 Month Price Forecast For UTHR
Distance to UTHR Price Forecasts
UTHR Price Momentum
🤔 Considering United Therapeutics (UTHR)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: January 23, 2025 5:55 AM UTC
UTHR Analyst Ratings & Price Targets
Based on our analysis of 19 Wall Street analysts, UTHR has a consensus that is bullish. The median price target is $385.61, with forecasts ranging from $302.00 to $600.00. Currently, there are 9 Buy ratings, 6 Hold ratings, and 1 Sell ratings.
With UTHR currently trading at $371.28, the median price forecast suggests a 3.9% upside. The most optimistic forecast comes from Hartaj Singh at Oppenheimer, projecting a 61.6% upside, while Chris Shibutani at Goldman Sachs provides the most conservative target, suggesting a -18.7% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
UTHR Analyst Consensus
UTHR Price Target Range
Latest UTHR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for UTHR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 8, 2025 | UBS | Ashwani Verma | Buy | Maintains | $475.00 |
| Nov 1, 2024 | Goldman Sachs | Chris Shibutani | Neutral | Maintains | $302.00 |
| Oct 31, 2024 | Argus Research | Jasper Hellweg | Buy | Maintains | $400.00 |
| Oct 31, 2024 | Oppenheimer | Hartaj Singh | Outperform | Maintains | $600.00 |
| Oct 31, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $425.00 |
| Oct 31, 2024 | Ladenburg Thalmann | Matthew Kaplan | Buy | Maintains | $344.00 |
| Oct 21, 2024 | TD Cowen | Joseph Thome | Buy | Maintains | $400.00 |
| Sep 23, 2024 | Jefferies | Eun Yang | Buy | Maintains | $432.00 |
| Aug 28, 2024 | Oppenheimer | Hartaj Singh | Outperform | Maintains | $575.00 |
| Aug 20, 2024 | Wells Fargo | Tiago Fauth | Overweight | Maintains | $380.00 |
| Aug 1, 2024 | B of A Securities | Greg Harrison | Underperform | Maintains | $280.00 |
| Aug 1, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $400.00 |
| Jul 25, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $400.00 |
| Jul 11, 2024 | Morgan Stanley | Terence Flynn | Equal-Weight | Downgrade | $321.00 |
| Jul 11, 2024 | TD Cowen | Joseph Thome | Buy | Maintains | $350.00 |
| Jul 8, 2024 | UBS | Ashwani Verma | Buy | Maintains | $370.00 |
| Jun 12, 2024 | Wells Fargo | Tiago Fauth | Overweight | Maintains | $350.00 |
| May 21, 2024 | JP Morgan | Jessica Fye | Overweight | Maintains | $300.00 |
| May 3, 2024 | Goldman Sachs | Chris Shibutani | Neutral | Maintains | $240.00 |
| May 2, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $300.00 |
Stocks Similar to United Therapeutics Corp
The following stocks are similar to United Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
United Therapeutics Corp (UTHR) Financial Data
United Therapeutics Corp has a market capitalization of $16.43B with a P/E ratio of 16.2x. The company generates $2.76B in trailing twelve-month revenue with a 40.3% profit margin.
Revenue growth is +22.9% quarter-over-quarter, while maintaining an operating margin of +54.5% and return on equity of +18.8%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
United Therapeutics Corp (UTHR) Company Overview
About United Therapeutics Corp
Develops biotechnology products for chronic diseases.
The company generates revenue by developing and commercializing innovative therapies for chronic and life-threatening conditions, particularly focusing on pulmonary arterial hypertension (PAH) and neuroblastoma. It sells a range of products, including inhaled therapies and injectable medications, directly to healthcare providers and through partnerships with other companies.
United Therapeutics is actively engaged in research and development, with several products in the pipeline, including gene therapy and novel delivery systems for existing medications. The company has established collaborations with other firms to enhance its product development capabilities and expand its market reach. Founded in 1996 and based in Silver Spring, Maryland, United Therapeutics is committed to addressing unmet medical needs in patient care.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
1,168
CEO
Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.
Country
United States
IPO Year
1999
Website
www.unither.comUnited Therapeutics Corp (UTHR) Latest News & Analysis
United Therapeutics Corporation (Nasdaq: UTHR) will present five posters and participate in two talks at the PVRI 2025 Annual Congress in Rio de Janeiro from January 29 to February 1, 2025.
The presentation of research at a major congress highlights United Therapeutics' commitment to innovation in pulmonary hypertension, potentially boosting investor confidence in its growth prospects.
Zacks Style Scores can assist investors in selecting strong, market-beating stocks for their investment portfolios.
Zacks Style Scores provide a systematic approach to identifying stocks with potential for strong performance, aiding investors in making informed decisions for their portfolios.
United Therapeutics (UTHR) and AnaptysBio, Inc. (ANAB) have been compared to their sector's performance for the year. Further details on their specific performance metrics weren't provided.
Performance comparison signals potential investment opportunities or risks in United Therapeutics and AnaptysBio relative to their sector, influencing portfolio decisions.
Zacks Style Scores can assist investors in selecting strong stocks that may outperform the market for their investment portfolios.
The Zacks Style Scores can guide investors in selecting stocks with potential for outperformance, aiding in portfolio optimization and enhancing returns.
Investors are comparing United Therapeutics (UTHR) and Stevanato Group (STVN) for value investment opportunities in the Medical - Drugs sector.
The comparison of United Therapeutics and Stevanato Group highlights potential investment opportunities in the Medical - Drugs sector, crucial for value investors seeking undervalued stocks.
United Therapeutics Corporation to Present at the 43rd Annual J.P. Morgan Healthcare Conference
17 days agoUnited Therapeutics Corporation (Nasdaq: UTHR) will present an overview of its business at the J.P. Morgan Healthcare Conference on January 13, 2025, from 2:15 to 2:55 PM PST.
United Therapeutics' upcoming presentation at a major healthcare conference could impact stock performance by influencing investor sentiment and providing insights into future growth prospects.
Frequently Asked Questions About UTHR Stock
What is United Therapeutics Corp's (UTHR) stock forecast for 2025?
Based on our analysis of 19 Wall Street analysts, United Therapeutics Corp (UTHR) has a median price target of $385.61. The highest price target is $600.00 and the lowest is $302.00.
Is UTHR stock a good investment in 2025?
According to current analyst ratings, UTHR has 9 Buy ratings, 6 Hold ratings, and 1 Sell ratings. The stock is currently trading at $371.28. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for UTHR stock?
Wall Street analysts predict UTHR stock could reach $385.61 in the next 12 months. This represents a 3.9% increase from the current price of $371.28. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is United Therapeutics Corp's business model?
The company generates revenue by developing and commercializing innovative therapies for chronic and life-threatening conditions, particularly focusing on pulmonary arterial hypertension (PAH) and neuroblastoma. It sells a range of products, including inhaled therapies and injectable medications, directly to healthcare providers and through partnerships with other companies.
What is the highest forecasted price for UTHR United Therapeutics Corp?
The highest price target for UTHR is $600.00 from Hartaj Singh at Oppenheimer, which represents a 61.6% increase from the current price of $371.28.
What is the lowest forecasted price for UTHR United Therapeutics Corp?
The lowest price target for UTHR is $302.00 from Chris Shibutani at Goldman Sachs, which represents a -18.7% decrease from the current price of $371.28.
What is the overall UTHR consensus from analysts for United Therapeutics Corp?
The overall analyst consensus for UTHR is bullish. Out of 19 Wall Street analysts, 9 rate it as Buy, 6 as Hold, and 1 as Sell, with a median price target of $385.61.
How accurate are UTHR stock price projections?
Stock price projections, including those for United Therapeutics Corp, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
